Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Regulação e direito · 29/11/20171 min de leitura
Prospective Grant of Exclusive Patent Commercialization License: N6, A Novel, Broad, Highly Potent HIV-Specific Antibody
Tradução automática local · Idioma original da fonte
Resumo
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to GlaxoSmithKline Intellectual Property Development Ltd (GSK) located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Idioma original da fonte: Federal Register — All DocumentsAbrir o comunicado original →